This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
I'm PortAI, I can summarize articles.
Top Wall Street analysts have initiated coverage on several companies with bullish ratings. Guggenheim's Debjit Chattopadhyay rated Entrada Therapeutics (NASDAQ:TRDA) as Buy with a $20 target. Stifel's Laura Prendergast rated BridgeBio Oncology (NASDAQ:BBOT) as Buy with a $23 target and Olema Pharmaceuticals (NASDAQ:OLMA) with a $48 target. Goldman Sachs' Brian Lee rated Energy Fuels (AMEX:UUUU) as Buy with a $30 target. Current share prices are $10.82, $10.84, $21.76, and $23.37 respectively for these companies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments